

Supporting Information

Triple-locked fluorescent probes sequentially activated by hNQO1, LAP and FA: application in bioimaging of cancer cells

Langping Zhou, Han Chen, Weibing Zhang*, Junhong Qian*

Shanghai Key Laboratory of Functional Materials Chemistry, School of Chemistry & Molecular Engineering, East
China University of Science and Technology, Shanghai, 200237, China.

*Corresponding author: Tel: +86-21-64252145; Fax: +86-21-64233161

E-mail: junhongqian@ecust.edu.cn; weibingzhang@ecust.edu.cn

Contents

Experimental section	2
¹ H-NMR spectra of NP2-But and NP2-Bio	5
¹ H-NMR, ¹³ C-NMR and ESI-Mass spectra of NP3-But	6
¹ H-NMR, ¹³ C-NMR and ESI-Mass spectra of NP3-Bio	7
Normalized absorption and emission spectra of NP3-Bio	8
Spectral response of NP3-Bio toward FA, LAP and hNQO1	9
The absorption and emission spectra of NP3-Bio under different conditions	10
Time-dependent absorption and emission spectra and plots of fluorescence intensity ratios vs pH	11
Frontier molecular orbitals of NP3-But/Bio , NP2-But/Bio , NP1-But/Bio and NP-But/Bio	12
Cell viabilities of various cell lines incubated with NP3-But and NP3-Bio	13
Confocal fluorescence imaging of L929 and HeLa cells incubated with NP2-But and NP3-But	14
Confocal fluorescence imaging of HeLa and HepG-2 cells incubated with NP3-But	15
Confocal fluorescence imaging of HeLa and HepG-2 cells incubated with NP3-Bio	16
Comparison of NP3-But and NP3-Bio with some reported probes	17
References	18

NP3-But and NP3-Bio: A solution of DMF (5 mL) containing **QPA** (30 mg, 0.12 mmol), HOBt (20 mg, 0.14 mmol), EDC (28 mg, 0.14 mmol) and TEA (30 μ L, 0.22 mmol) was stirred at room temperature for 1 h. Then 80 mg of **NP2-But** (0.12 mmol) was added into the above solution. After stirred for another 12 h, the solvent was evaporated under reduced pressure and the crude product was purified with column chromatography (DCM:MeOH = 50:3, v:v) to afford a yellow solid **NP3-But** (60 mg, 80%). ^1H NMR (400 MHz, CDCl_3) δ (ppm): 8.53 (d, J = 2.2 Hz, 1H), 8.39 (d, J = 7.2 Hz, 1H), 8.35 (d, J = 8.2 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 2.2 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 6.08 (d, J = 8.1 Hz, 1H), 4.59-4.49 (m, 1H), 4.17-4.12 (m, 2H), 3.10 (d, J = 14.6 Hz, 1H), 2.80 (d, J = 14.6 Hz, 1H), 2.19 (s, 3H), 1.94 (d, J = 1.3 Hz, 3H), 1.92 (d, J = 1.3 Hz, 3H), 1.73-1.62 (m, 7H), 1.45 (s, 6H), 1.00-0.91 (m, 9H). ^{13}C NMR (151 MHz, CDCl_3) δ (ppm): 191.70, 187.87, 172.97, 172.20, 164.16, 163.90, 151.70, 148.54, 143.00, 139.43, 139.06, 132.99, 130.86, 128.95, 126.10, 125.55, 122.78, 119.69, 114.54, 106.00, 49.81, 48.98, 40.13, 39.64, 39.06, 30.23, 29.78, 29.66, 24.84, 22.74, 22.02, 20.45, 14.12, 13.88, 12.69, 12.24. ESI-MS: m/z ($\text{M}+\text{H}$) $^+$ calcd 629.3339, found 629.3338. **NP3-Bio** was obtained by the same procedure with **NP2-Bio** instead of **NP2-But**. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ (ppm): 10.38 (s, 1H), 9.58 (s, 1H), 8.66 (d, J = 8.5 Hz, 1H), 8.47 (d, J = 7.3 Hz, 1H), 8.30 (d, J = 7.7 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.74 (t, J = 7.9 Hz, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 6.34 (s, 1H), 4.38 (q, J = 7.8 Hz, 1H), 4.28 (t, J = 6.5 Hz, 1H), 4.12 (d, J = 5.6 Hz, 1H), 4.00 (q, J = 6.4 Hz, 4H), 3.10-3.05 (m, 1H), 2.85-2.75 (m, 3H), 2.55 (d, J = 12.4 Hz, 1H), 2.27 (t, J = 7.4 Hz, 2H), 2.06 (s, 3H), 1.95 (s, 3H), 1.91 (s, 3H), 1.69-1.43 (m, 13H), 1.38-1.36 (m, 4H), 1.35-1.32 (m, 6H), 0.95 (d, J = 6.5 Hz, 3H), 0.86 (d, J = 6.4 Hz, 3H). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ (ppm): 190.70, 187.34, 173.37, 172.48, 172.11, 164.14, 163.39, 163.18, 155.05, 151.05, 144.27, 136.88, 136.25, 133.70, 131.36, 129.43, 128.92, 125.56, 122.50, 119.33, 111.13, 105.39, 64.12, 61.49, 59.64, 55.82, 49.96, 47.76, 40.73, 40.50, 38.22, 33.80, 28.62, 28.49, 28.44, 27.98, 26.64, 25.67, 24.99, 24.71, 23.30, 22.53, 22.00, 14.43, 14.23, 13.25, 12.23. ESI-MS: m/z ($\text{M}+\text{H}$) $^+$ calcd 899.4377, found 899.4376.

Spectral measurements

All stock solutions, including 3 mmol/L of **NP3-But** and **NP3-Bio** in DMSO, 1 mg/mL of hNQO1 in PBS (100 mmol/L, pH 7.40, containing 100 mmol/L KCl and 0.007% BSA), 30 mmol/L of NADH in PBS, 10 U/ml of LAP in PBS, 30 mmol/L of FA in PBS, 30 mmol/L of dicumarol and bestatin in DMSO, 30 mmol/L of amino acids/ions (NaHSO_3 , Na_2S , DTT, Lys, Gly, L-Arg, L-Glu, GSSG, GSH, Hcy, Cys, glucose, NH_4^+ , Mg^{2+} , Cu^{2+} , NO_3^- , SO_4^{2-} , Cl^-) in Tris-HCl or (NAC, His, Met, Trp) in DMSO and 30 mg/mL of proteins (HSA, BSA, OVA, α -chy, β -lac, mucin, pepsin, tripsin) in PBS were prepared in advance. The excitation/emission wavelengths were 425 nm/535 nm.

Dynamic experiments. Stock solution of the probes (10 μ L), hNQO1 (30 μ L), NADH (10 μ L), LAP (150 μ L) and FA (13.3 μ L) were added to 3 mL of buffer solution. The absorption and emission spectra of the above solution were detected at different times.

pH effect. The pH of the probes (10 μ M) and reaction products (10 μ M) in PBS were adjusted with NaOH or HCl aqueous solution, and then recorded the emission spectra of the above solutions with different pH values.

Selectivity. Stock solutions of amino acids/ions (50 μ L) or proteins (100 μ L) were added to 3 mL of PBS containing probes (10 μ mol/L). The fluorescence spectra were measured after the mixture equilibrium for 90 min.

High-performance liquid chromatography (HPLC) traces

HPLC spectra were obtained on an iChrom 5100 LC system and a Sinopak C18 reversed-phase column (4.6 mm × 25 cm). The mobile phase was degassed with an ultrasonic device for 10 minutes. Mobile phase: A-water, B-acetonitrile; injection volume: 20 µL; flow rate: 1.0 mL/min; detection wavelength: 440 nm; elution condition: gradient elution, 0-30 min 5-95% B.

Computational methods

The density functional theory (DFT) was employed to optimize the structures of the probes through Gaussian 16. All structure optimizations were performed using DFT-M062X functionals and Def2SVP basis set for the ground states. Solvation effects were taken into account using the SMD mode and the solvent was water. Frequency calculations were performed to confirm that we obtained stable structures without imaginary vibrational frequencies.

MTT Assay

L929, MDA-MB-231, HeLa and HepG-2 cell lines (National Collection of Authenticated Cell Cultures, Shanghai, China) were cultured in Dulbecco's Modified Eagle Medium (High glucose) containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C in an atmosphere of 5% CO₂. The cells were transferred to 96-well plate (5000 cells/well) and incubated for 24 h. After removal of the medium, the cells were cultured with different concentrations (0-20 µM) of probes in serum-free DME medium for 24 h followed by incubated with 5 mg/mL of MTT for another 4 h. After removal of the medium, 100 µL of DMSO were added to the plate. The absorbance at 570 nm of each solution was measured with a microplate reader. The cell viability was calculated according to the following equation.

$$\text{Cell viability (\%)} = (\text{OD}_{\text{sample}} - \text{OD}_{\text{blank}}) / (\text{OD}_{\text{control}} - \text{OD}_{\text{blank}}) \times 100\%$$

Where OD_{control} and OD_{sample} are the optical densities of the wells in which the cells incubated without and with certain concentration of the probe, respectively; OD_{blank} represents optical density of the well only containing culture medium and MTT.

Confocal fluorescent imaging

The cells were transferred to confocal dishes and incubated for 24 h, and followed by washed with PBS (20 mmol/L, pH 7.4) for three times. Then the cells were cultured with serum-free DME medium containing probes (10 µmol/L) for 30 min and washed with PBS for three times again. For the control experiments, before incubation with 10 µmol/L of probes, the cells were pre-incubated with 500 µmol/L dicumarol for 6 h, 100 µmol/L bestatin for 1 h, 200 µmol/L NaHSO₃ for 30 min, 1 µg/mL LPS for 12 h or 1 µg/mL hNQO1 (containing 100 µmol/L NADH) for 30 min and washed with PBS. The fluorescence was collected at 425-475 nm for the blue channel and 500-550 nm for the green channel as excited at 405 nm and 488 nm, respectively.




Fig. S1 ^1H -NMR spectra of NP2-But and NP2-Bio.




Fig. S2 $^1\text{H-NMR}$, $^{13}\text{C-NMR}$ and ESI-Mass spectra of NP3-But.




Fig. S3 ¹H-NMR, ¹³C-NMR and ESI-Mass spectra of NP3-Bio.




Fig. S4 Normalized absorption and emission spectra of the probes in PBS (100 mM, pH 7.4).
 $[\text{probe}] = 10 \mu\text{M}$, $\lambda_{\text{ex}} = 425 \text{ nm}$.




Fig. S5 The absorption (a) and emission (b) spectra of **NP3-Bio** under different conditions. [NP3-Bio] = 10 μ M, [hNQO1] = 10 μ g/mL, [LAP] = 0.5 U/mL, [FA] = 200 μ M, [NADH] = 20 μ M, λ_{ex} = 425 nm.




Fig. S6 Time-dependent absorption (a, c) and emission (b, d) spectra of the quaternary systems (NP3-But/NP3-Bio + FA + LAP + hNQO1); (e) plots of the fluorescence intensity ratios of the quaternary systems as a function of time. [NP3-But/NP3-Bio] = 10 μ M, [FA] = 200 μ M, [LAP] = 0.5 U/mL, [hNQO1] = 10 μ g/mL, [NADH] = 20 μ M, λ_{ex} = 425 nm, λ_{em} = 530 nm.




Fig. S7 Plots of the fluorescence intensities of different compounds as a function of pH. [probe] = 10 μ M, λ_{ex} = 425 nm, λ_{em} = 530 nm.




Fig. S8 Frontier molecular orbitals of NP3-But/Bio and their reaction products at different stages (NP2-But/Bio, NP1-But/Bio and NP-But/Bio).





Fig. S9 The viabilities of various cell lines treated with NP3-But and NP3-Bio.




Fig. S10 Confocal fluorescence imaging of L929 (a-d, f-i) and HeLa (e, j) cells stained with 10 μ M **NP2-But** (a-e) and **NP3-But** (f-j); pre-treated with 1 μ g/mL hNQO1 for 30 min (b, g), 1 μ g/mL LPS for 12 h (c, h) or 1 mM CoCl₂ for 24 h (d, i). (1) Merged of (2), (3) and (4); (2) blue channel; (3) green channel; (4) bright field.




Fig. S11 Confocal fluorescence imaging of HepG-2 (a-d) and HeLa (e-h) cells stained with 10 μM **NP3-But**. Pre-treated with 500 μM Dic for 6 h (b, f), 100 μM BST for 1 h (c, g) or 200 μM NaHSO₃ for 30 min (d, h). (1) Merged of (2), (3) and (4); (2) blue channel; (3) green channel; (4) bright field.













Fig. S12 Confocal fluorescence imaging of HepG-2 (a-e) and HeLa (f-j) cells stained with 10 μ M NP3-Bio. Pre-treated with 500 μ M Dic for 6 h (b, g), 100 μ M BST for 1 h (c, h) or 200 μ M NaHSO₃ for 30 min (d, i) or 1 mM biotin for 30 min (e, j). (1) Merged of (2), (3) and (4); (2) blue channel; (3) green channel; (4) bright field.

Table S1 Comparison of **NP3-But** and **NP3-Bio** with some reported probes

Analytes	Chemical structure	Distinguish between cells	Literature
hNQO1		normal cells (H596) vs cancer cells (HT-29, OVCAR-3)	[2]
hNQO1 + H ₂ S		normal cells (HEK293T cells) vs colorectal cancer cells (HT29, HCT116 cells)	[3]
hNQO1 + APN		normal cells (L02, Hek293, L929, LX-2 cells) vs cancer cells (A549, HepG-2, MCF-7 cells)	[4]
LAP		normal liver cells (L02 cells) vs liver cancer cells (HepG-2 cells)	[5]
LAP + viscosity + polarity		different types of inflammatory cells (L02 cells induced by different drugs)	[6]
LAP + GSH		normal liver cells (L02 cells) vs liver cancer cells (HepG2, Hepa1-6 cells)	[7]
FA		Lysosomal formaldehyde in EC1 cells	[8]
FA + viscosity		mitochondrial viscosity and FA in HeLa cells	[9]
FA + pH		Lysosomal formaldehyde in HeLa cells	[10]
FA + LAP + hNQO1	NP3-But	inflammatory L929 / MDA-MB-231 cells vs HeLa/HepG-2 cells	This work
FA + LAP + hNQO1	NP3-Bio	hypoxic L929 / MDA-MB-231 cells vs HeLa/HepG-2 cells	

References

- [1] L. Zhou, J. Cui, Z. Yu, D. Zou, W. Zhang and J. Qian, *Sens. Actuators, B*, 2021, **332**, 129494.
- [2] Y. Zheng, D. Pan, Y. Zhang, Y. Zhang and Y. Shen, *Anal. Chim. Acta*, 2019, **1090**, 125-132.
- [3] Y. Cha, Y. Song, C. Jung, Y. Ko and M. H. Lee, *Sens. Actuators, B*, 2025, **436**, 137682.
- [4] Y. Shen, W. Li, Z. Zhou, J. Xu, Y. Li, H. Li, X. Zheng, S. Liu, X. B. Zhang and L. Yuan, *Angew. Chem. Int. Ed.*, 2024, **63**, e202406332.
- [5] D. Yuan, Z. Xu, B. Zhang, X. Yin, J. Ye, X. Zhou and L. Wang, *Chem. Commun.*, 2022, **58**, 8364-8367.
- [6] R. Li, J. Guo, Y. Duan, X. Liu, L. Gui, Y. Xu, X. Kong, Y. Li, H. Chen and Z. Yuan, *Chem. Eng. J.*, 2022, **435**, 135043.
- [7] X. Xia, M. Huang, Y. Hu, Z. Zhou, Y. Chen, J. Wang, J. Ren, E. Wang and F. Wang, *Anal. Chem.*, 2024, **96**, 18898-18906.
- [8] M. Wang, X. Zhang, L. Wang, J. Zhang, N. Liu and D. Zhang, *Microchem. J.*, 2023, **191**, 108761.
- [9] F. Liang, W. Huang, L. Wu, Y. Wu, T. Zhang, X. He, Z. Wang, X. Yu, Y. Li and S. Qian, *Analyst*, 2023, **148**, 1437-1441.
- [10] Z. Xie, B. Yin, J. Shen, D. Hong, L. Zhu, J. Ge and Q. Zhu, *Org. Biomol. Chem.*, 2018, **16**, 4628-4632.